[{"id":"18a31d2f-4fc8-4aec-b7b2-91da3287927e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03273452","created_at":"2021-01-18T16:10:03.757Z","updated_at":"2024-07-02T16:37:17.600Z","phase":"Phase 2","brief_title":"Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma (PET: Prednisone, Etoposide and Thalidomide)","source_id_and_acronym":"NCT03273452","lead_sponsor":"Qingdao University","biomarkers":" CD20 • PD-1 • BCL6 • CD4 • CXCL13 • MME • CR1","pipe":"","alterations":" ","tags":["CD20 • PD-1 • BCL6 • CD4 • CXCL13 • MME • CR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e etoposide IV • prednisone • Epidaza (chidamide) • thalidomide"],"overall_status":"Unknown status","enrollment":" Enrollment 30","initiation":"Initiation: 03/01/2017","start_date":" 03/01/2017","primary_txt":" Primary completion: 02/01/2019","primary_completion_date":" 02/01/2019","study_txt":" Completion: 05/01/2019","study_completion_date":" 05/01/2019","last_update_posted":"2017-09-25"}]